HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · CJC-1295 without DAC + Ipamorelin
GH-secretagogue blend · research-use
CJC-1295 no-DAC + Ipamorelin OEM supply.
Lyophilized GHRH-analog and ghrelin-receptor-agonist blend in 10 mg vials, supplied to research labs and private-label brands with per-component batch-linked COA, HPLC chromatogram and MS identity documentation.
CJC-1295 without DAC + IpamorelinHPLC ≥ 99%MS confirmed10mg
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | CJC-1295 without DAC + Ipamorelin |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 10mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Lyophilized powder stable at 2–8 °C protected from light; −20 °C for long-term storage. After reconstitution with bacteriostatic water, keep refrigerated and use within the validated window. |
MOQ & lead time
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | 1 kit (10 vials) | 3–7 days |
| Production lot | 200–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
About CJC-1295 without DAC + Ipamorelin.
The blend combines two growth-hormone secretagogues that act on complementary receptors: CJC-1295 without DAC (Modified GRF 1-29) is a synthetic growth-hormone-releasing hormone (GHRH) analog that binds the GHRH receptor, while ipamorelin is a selective agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). In research models the two are frequently co-formulated to study additive stimulation of somatotroph growth-hormone release.
Documentation
Batch documentation support for CJC-1295 without DAC + Ipamorelin lots.
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
MS identity
Mass spectrometry identity confirmation against the CJC-1295 without DAC + Ipamorelin reference profile.
Lot traceability
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
CJC-1295 without DAC + Ipamorelin — frequently asked by B2B buyers.
What exactly is in the CJC-1295 without DAC + Ipamorelin blend?
Each vial contains two lyophilized peptides co-formulated together: CJC-1295 without DAC — also called Modified GRF (1-29), a GHRH analog — and ipamorelin (CAS 170851-70-4), a selective ghrelin-receptor agonist. The per-vial ratio and total peptide content are stated on the batch documentation and confirmed on RFQ.
Do you provide a single CAS number and molecular weight for the blend?
No — a blend is a physical mixture of two distinct peptides, so it has no single CAS number or molecular weight. We report identity, purity and mass data for each component separately on the batch COA and MS report rather than assigning one figure to the mixture.
What documentation ships with each lot?
Every lot ships with a batch COA, HPLC purity chromatograms and MS identity confirmation for each peptide, plus water-content and appearance notes. Current-batch documentation is available for review before payment on qualifying orders.
What vial size and minimum order apply?
The blend is stocked as lyophilized powder in 10 mg vials with a minimum order of 1 kit (10 vials). Fill ratios, alternative vial sizes and private-label / OEM packaging can be quoted on request.
Is this product sold for therapeutic or consumer use?
No. It is supplied strictly as a research-use reference material for laboratory and manufacturing customers. We confirm buyer context and destination country before invoicing and do not provide dosing or medical guidance.
Related compounds